TY - JOUR
T1 - 2017 in review
T2 - FDA approvals of new molecular entities
AU - Kinch, Michael S.
AU - Griesenauer, Rebekah H.
PY - 2018/8
Y1 - 2018/8
N2 - An overview of drugs approved by the FDA in 2017 reflected a reversion to the mean after a low number of NME approvals in 2016. This reversal was largely driven by the largest number of biologics-based NMEs recorded to date, which offset an average number of small-molecule approvals. Oncology indications continued to dominate followed by novel treatments for infectious, immunologic and neurologic diseases. From a mechanistic standpoint, the industry has continued a trend of target diversification, reflecting advances in scientific understanding of disease processes. Finally, 2017 continued a period of relatively few mergers and acquisitions, which broke a more-than-a-decade-long decline in the number of organizations contributing to research and development.
AB - An overview of drugs approved by the FDA in 2017 reflected a reversion to the mean after a low number of NME approvals in 2016. This reversal was largely driven by the largest number of biologics-based NMEs recorded to date, which offset an average number of small-molecule approvals. Oncology indications continued to dominate followed by novel treatments for infectious, immunologic and neurologic diseases. From a mechanistic standpoint, the industry has continued a trend of target diversification, reflecting advances in scientific understanding of disease processes. Finally, 2017 continued a period of relatively few mergers and acquisitions, which broke a more-than-a-decade-long decline in the number of organizations contributing to research and development.
UR - http://www.scopus.com/inward/record.url?scp=85048746590&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2018.05.011
DO - 10.1016/j.drudis.2018.05.011
M3 - Short survey
C2 - 29751111
AN - SCOPUS:85048746590
SN - 1359-6446
VL - 23
SP - 1469
EP - 1473
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 8
ER -